BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26769004)

  • 21. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
    Chakkalakal SA; Zhang D; Culbert AL; Convente MR; Caron RJ; Wright AC; Maidment AD; Kaplan FS; Shore EM
    J Bone Miner Res; 2012 Aug; 27(8):1746-56. PubMed ID: 22508565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
    Katagiri T; Tsukamoto S; Kuratani M
    Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
    Fukuda T; Kohda M; Kanomata K; Nojima J; Nakamura A; Kamizono J; Noguchi Y; Iwakiri K; Kondo T; Kurose J; Endo K; Awakura T; Fukushi J; Nakashima Y; Chiyonobu T; Kawara A; Nishida Y; Wada I; Akita M; Komori T; Nakayama K; Nanba A; Maruki Y; Yoda T; Tomoda H; Yu PB; Shore EM; Kaplan FS; Miyazono K; Matsuoka M; Ikebuchi K; Ohtake A; Oda H; Jimi E; Owan I; Okazaki Y; Katagiri T
    J Biol Chem; 2009 Mar; 284(11):7149-56. PubMed ID: 18684712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva.
    Shi S; Cai J; de Gorter DJ; Sanchez-Duffhues G; Kemaladewi DU; Hoogaars WM; Aartsma-Rus A; 't Hoen PA; ten Dijke P
    PLoS One; 2013; 8(7):e69096. PubMed ID: 23861958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].
    Katagiri T; Kamizono J; Nakashima Y; Kitoh H; Susami T; Haga N
    Clin Calcium; 2010 Oct; 20(10):1510-7. PubMed ID: 20890033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting.
    Kaplan J; Kaplan FS; Shore EM
    Gene Ther; 2012 Jul; 19(7):786-90. PubMed ID: 22011642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drosophila models of FOP provide mechanistic insight.
    Le V; Anderson E; Akiyama T; Wharton KA
    Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
    Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
    Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
    Hino K; Horigome K; Nishio M; Komura S; Nagata S; Zhao C; Jin Y; Kawakami K; Yamada Y; Ohta A; Toguchida J; Ikeya M
    J Clin Invest; 2017 Sep; 127(9):3339-3352. PubMed ID: 28758906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP).
    Fiori JL; Billings PC; de la Peña LS; Kaplan FS; Shore EM
    J Bone Miner Res; 2006 Jun; 21(6):902-9. PubMed ID: 16753021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
    Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
    Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
    J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressiva.
    Lees-Shepard JB; Yamamoto M; Biswas AA; Stoessel SJ; Nicholas SE; Cogswell CA; Devarakonda PM; Schneider MJ; Cummins SM; Legendre NP; Yamamoto S; Kaartinen V; Hunter JW; Goldhamer DJ
    Nat Commun; 2018 Feb; 9(1):471. PubMed ID: 29396429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
    Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
    J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variable signaling activity by FOP ACVR1 mutations.
    Haupt J; Xu M; Shore EM
    Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.
    Kaplan FS; Glaser DL; Pignolo RJ; Shore EM
    Expert Opin Biol Ther; 2007 May; 7(5):705-12. PubMed ID: 17477807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.
    Haupt J; Deichsel A; Stange K; Ast C; Bocciardi R; Ravazzolo R; Di Rocco M; Ferrari P; Landi A; Kaplan FS; Shore EM; Reissner C; Seemann P
    Hum Mol Genet; 2014 Oct; 23(20):5364-77. PubMed ID: 24852373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.